Design and synthesis of deuterated boceprevir analogs with enhanced pharmacokinetic properties |
| |
Authors: | Adam J. Morgan Sophia Nguyen Vinita Uttamsingh Gary Bridson Scott Harbeson Roger Tung Craig E. Masse |
| |
Affiliation: | Concert Pharmaceuticals, , Lexington, MA, 02421 USA |
| |
Abstract: | As part of an ongoing effort to apply the Deuterated Chemical Entity Platform (DCE Platform?) to clinically validated drugs, the synthesis of deuterated analogs of the hepatitis C virus protease inhibitor boceprevir was carried out. The devised synthetic routes allowed for site‐selective deuterium incorporation with high levels of isotopic purity. Application of the DCE Platform? to boceprevir enabled the identification of several deuterated analogs that display marked levels of in vitro metabolic stabilization. Most notably, analog 1g exhibits a near doubling of in vitro half‐life in human liver microsomal assays. The details of the convergent synthetic route to the boceprevir isotopologs and the results of the metabolic stability assays are described herein. |
| |
Keywords: | deuteration DCE Platform boceprevir HCV NS3 protease KIE |
|